Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Innocan Pharma Corp C.INNO

Alternate Symbol(s):  INNPF

Healthcare
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.


CSE:INNO - Post by User

Innocan Pharma Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Post by dkeller85on Jan 11, 2022 8:33am
216 Views
Post# 34302801

Why this Canadian-Israeli Stock Grew 121% This Year

Why this Canadian-Israeli Stock Grew 121% This Year"Innocan Pharma operates three primary and distinct segments: research and development (R&D) of CBD-loaded exosomes, R&D of the use of CBD-loaded liposomes, and commercialization and sale of branded CBD-integrated pharmaceutical and topical treatment products."

tldr; INNO is bullish going into 2022, expect less volatility amidst ongoing gains as Innocan pushes towards its target price.

"https://www.entrepreneur.com/article/412265"
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities